Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report

Fig. 1

The chest computed tomography (CT) scan images showing the locations of tumor lesions found in a left pleural effusion of lung when the patient presented with dyspnea in June 2019; b after thoracentesis, two metastatic nodules in the left lower lobe; c after accepted PD-1 inhibitor Camrelizumab, 200 mg/time, twice per week, for a total of 4 injections (2 cycles), the tumor nodules were still increased, indicating the disease progressed; d After taking larotectinib, 200 mg/day, orally for 1 month, some lesions showed decreased in size; e oral administration of larotectinib for 3 months indicated some cancerous lesions were continuously reduced in size; f Oral administration of larotectinib for 6 months showed that some cancerous lesions either are reducing or even disappeared

Back to article page